血必净注射液通过PI3K/Akt/FOXO1信号通路上调claudin-5表达改善ARDS肺血管屏障功能
该研究用脂多糖(LPS)诱导大鼠和人肺微血管内皮细胞(HPMECs)ARDS模型,探讨血必净注射液上调claudin-5表达的信号通路。体内实验中,血必净干预组较LPS组肺湿干重比降低(4.92±0.38 vs. 6.79±0.42,P<0.01),claudin-5、p-Akt/t-Akt、p-FOXO1/t-FOXO1表达均升高(均P<0.01)。体外实验中,PI3K抑制剂LY294002干预后claudin-5表达较血必净干预组降低(0.41±0.02 vs. 0.80±0.08,P<0.01)。作者结论为血必净通过PI3K/Akt/FOXO1通路上调claudin-5表达改善ARDS肺血管屏障功能。
要点
- LPS组大鼠肺湿干重比较对照组升高(6.79±0.42 vs. 4.19±0.13),血必净干预后降至4.92±0.38(vs. LPS组,P<0.01)。
- LPS组肺组织claudin-5/GAPDH较对照组降低(0.33±0.03 vs. 1.03±0.07,P<0.01),血必净干预后升至0.53±0.05(vs. LPS组,P<0.01)。
- LPS组p-Akt/t-Akt较对照组降低(0.18±0.02 vs. 1.01±0.13,P<0.01),血必净干预后升至0.56±0.12(vs. LPS组,P<0.01)。
- LPS组p-FOXO1/t-FOXO1较对照组降低(0.16±0.06 vs. 1.00±0.19,P<0.01),血必净干预后升至0.68±0.10(vs. LPS组,P<0.01)。
- 体外HPMECs中,LY294002干预组claudin-5/β-actin较血必净干预组降低(0.41±0.02 vs. 0.80±0.08,P<0.01)。
适用人群与场景
- 脂多糖(LPS)诱导的ARDS大鼠模型(雄性Sprague-Dawley大鼠)及人肺微血管内皮细胞(HPMECs)模型。
处置流程与药物剂量
- 体内实验:血必净对照组腹腔注射血必净注射液1 mg/kg,每日两次,连续3天;血必净干预组先给予血必净预处理后再注射LPS 10 mg/kg 12小时。
- 体外实验:血必净对照组以2 g/L血必净孵育24小时;血必净干预组先以2 g/L血必净孵育24小时,再以1 mg/L LPS孵育12小时;LY294002干预组先以10 μmol/L LY294002孵育1小时,再以2 g/L血必净孵育24小时,再以1 mg/L LPS孵育12小时。
研究设计与关键结果
- 研究类型:动物与细胞实验;体内实验20只雄性SD大鼠随机分为4组(每组5只):对照组、LPS组(LPS 10 mg/kg注射12小时)、血必净对照组(血必净1 mg/kg,每日两次,连续3天)、血必净干预组(血必净预处理后LPS注射)。
- 体内实验:LPS组肺湿干重比较对照组升高(6.79±0.42 vs. 4.19±0.13),血必净干预后较LPS组降低(4.92±0.38 vs. 6.79±0.42,P<0.01)。
- 体内实验:LPS组肺组织损伤较对照组严重,血必净干预后明显改善。
- 体内实验:LPS组claudin-5/GAPDH较对照组降低(0.33±0.03 vs. 1.03±0.07,P<0.01),血必净干预后较LPS组升高(0.53±0.05 vs. 0.33±0.03,P<0.01)。
- 体内实验:LPS组p-Akt/t-Akt较对照组降低(0.18±0.02 vs. 1.01±0.13,P<0.01),血必净干预后较LPS组升高(0.56±0.12 vs. 0.18±0.02,P<0.01)。
- 体内实验:LPS组p-FOXO1/t-FOXO1较对照组降低(0.16±0.06 vs. 1.00±0.19,P<0.01),血必净干预后较LPS组升高(0.68±0.10 vs. 0.16±0.06,P<0.01)。
- 体外实验:HPMECs分6组(每组5孔):对照组、血必净对照组(2 g/L血必净孵育24小时)、LY294002对照组(10 μmol/L LY294002孵育1小时)、LPS组(1 mg/L LPS孵育12小时)、血必净干预组(2 g/L血必净孵育24小时后1 mg/L LPS孵育12小时)、LY294002干预组(10 μmol/L LY294002孵育1小时后2 g/L血必净孵育24小时,再1 mg/L LPS孵育12小时)。
- 体外实验:LPS组claudin-5/β-actin较对照组降低(0.45±0.03 vs. 1.01±0.15,P<0.01);血必净干预组claudin-5/β-actin较对照组降低(0.80±0.08 vs. 1.01±0.15,P<0.01);LY294002干预组claudin-5/β-actin较血必净干预组降低(0.41±0.02 vs. 0.80±0.08,P<0.01)。
证据类型、等级与局限
- 证据类型:动物实验与体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:血必净注射液通过PI3K/Akt/FOXO1信号通路上调claudin-5表达,改善ARDS大鼠肺血管屏障功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To study the signaling pathway of the up-regulation of claudin-5 expression by Xuebijing injection.
METHODS: Animal and cell models of acute respiratory distress syndrome (ARDS) were induced by lipopolysaccharide (LPS). (1) In vivo study, 20 male Sprague-Dawley (SD) rats were randomly divided into 4 groups: control group, LPS group (LPS injection 10 mg/kg for 12 hours), Xuebijing control group (Xuebijing injection 1 mg/kg, twice a day, for 3 days), and Xuebijing intervention group (LPS injection after pretreatment of Xuebijing injection), according to random number method with 5 rats in each group. The lung tissues were taken to detect lung dry/wet weight ratio (W/D) and the morphological changes in each group. Claudin-5, phosphorylated forkhead box transcription factor O1 (p-FOXO1), total FOXO1 (t-FOXO1), phosphorylated Akt (p-Akt) and total Akt (t-Akt) in lung tissues were detected by immunohistochemical staining (IHC) and Western blotting. (2) In vitro study, human pulmonary microvascular endothelial cells (HPMECs) were divided into 6 groups (5 holes in each group): control group, Xubijing control group (incubated with 2 g/L Xubijing for 24 hours), phosphoinositide 3-kinases (PI3K) signaling pathway LY294002 control group (incubated with 10 μmol/L LY294002 for 1 hour), LPS group (incubated with 1 mg/L LPS for 12 hours), Xubijing intervention group (incubated with 2 g/L Xuebijing for 24 hours, then with 1 mg/L LPS for 12 hours) and LY294002 intervention group (incubated with 10 μmol/L LY294002 for 1 hour, then with 2 g/L and Xubijing for 24 hours, and then with 1 mg/L LPS for 12 hours). The expression levels of claudin-5, p-FOXO1, t-FOXO1, p-Akt and t-Akt of HPMECs in each group were assessed by Western blotting.
RESULTS: In vivo study: (1) Compared with the control group, the lung W/D ratio increased significantly in LPS group (6.79±0.42 vs. 4.19±0.13), and decreased significantly after the intervention of Xuebijing (4.92±0.38 vs. 6.79±0.42, P < 0.01). (2) Morphological changes of lung tissue: compared with the control group, the injury of lung tissue in LPS group was more serious, which was significantly improved after Xuebijing intervention. (3) Expression levels of claudin-5, p-Akt/t-Akt and p-FOXO1/t-FOXO1: the expression levels of claudin-5, p-Akt/t-Akt and p-FOXO1/t-FOXO1 in LPS group were significantly decreased as compared with the control group (claudin-5/GAPDH: 0.33±0.03 vs. 1.03±0.07, p-Akt/t-Akt: 0.18±0.02 vs. 1.01±0.13, p-FOXO1/t-FOXO1: 0.16±0.06 vs. 1.00±0.19, all P < 0.01). After the intervention of Xuebijing, the expression levels were significantly increased as compared with the LPS group (claudin-5/GAPDH: 0.53±0.05 vs. 0.33±0.03, p-Akt/t-Akt: 0.56±0.12 vs. 0.18±0.02, p-FOXO1/t-FOXO1: 0.68±0.10 vs. 0.16±0.06, all P < 0.01). In vitro study: compared with the control group, the expression level of claudin-5 in the LPS group was significantly decreased (claudin-5/β-actin: 0.45±0.03 vs. 1.01±0.15, P < 0.01), and the expression level of claudin-5 in Xuebijing intervention group was also significantly decreased (claudin-5/β-actin: 0.80±0.08 vs. 1.01±0.15, P < 0.01). After the intervention of LY294002, the expression of claudin-5 was significantly decreased as compared with the Xubijing intervention group (claudin-5/β-actin: 0.41±0.02 vs. 0.80±0.08, P < 0.01).
CONCLUSIONS: Xuebijing injection improve pulmonary vascular barrier function in rats with ARDS by up-regulating claudin-5 expression through PI3K/Akt/FOXO1 signaling pathway.
参考来源
- Geng P, Xiong J, Yu F, et al. [Xuebijing injection improve pulmonary vascular barrier function in ARDS by up-regulating claudin-5 expression through PI3K/Akt/FOXO1 signaling pathway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35387719. doi:10.3760/cma.j.cn121430-20211117-01732
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。